JEFFREY E GERSHENWALD to Mutation
This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Mutation.
Connection Strength
0.397
-
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021 04 27; 11(1):9043.
Score: 0.046
-
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017 08 14; 32(2):204-220.e15.
Score: 0.036
-
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
Score: 0.034
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.034
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.029
-
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15; 118(16):4014-23.
Score: 0.024
-
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet. 2011 Sep 25; 43(11):1119-26.
Score: 0.024
-
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011 May; 43(5):442-6.
Score: 0.023
-
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am. 2011 Jan; 20(1):165-80.
Score: 0.023
-
Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res. 2010 Nov; 8(11):1513-25.
Score: 0.022
-
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
Score: 0.016
-
Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol. 2024 Sep; 51(9):644-648.
Score: 0.014
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.009
-
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
Score: 0.008
-
Melanoma. Nat Rev Dis Primers. 2015 04 23; 1:15003.
Score: 0.008
-
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
Score: 0.007
-
A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget. 2014 May 30; 5(10):2912-7.
Score: 0.007
-
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.
Score: 0.007
-
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13481-6.
Score: 0.007
-
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013 Jul 01; 19(13):3611-20.
Score: 0.007
-
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35.
Score: 0.006
-
CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009 Jun; 19(3):146-55.
Score: 0.005
-
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 21; 99(8):1265-8.
Score: 0.005